

# Cyprotoex launches Cloe 'virtual human' software to support drug discovery

Submitted by: Lothbury Financial

Friday, 13 June 2003

---

Cyprotex launches Cloe PKä,  
"virtual human" software to support drug discovery

Cyprotex plc today unveils Cloe PKä, a novel and proprietary software system that accurately predicts, via its "virtual human" model, the pharmacokinetics (PK) of potential drug compounds. Using a unique combination of laboratory tests and sophisticated computer methods, Cloe PKä is attracting worldwide interest with several large pharmaceutical companies, who are currently trialling the software with a view to using it as a decision-making tool to support their drug discovery programmes.

Currently less than 2% of drug discovery projects succeed. Cloe PKä aims to help increase these success rates by enabling pharmaceutical companies to discover problematic compounds earlier in the process allowing the company to focus on the most promising compounds without significant time loss or cost.

Drug discovery is a time-consuming and expensive practice that requires the use of laboratory animals to test whether a compound lingers in the body long enough to be an effective drug. Cyprotex's Cloe PKTM model can be applied at the earliest stages in the drug discovery process, effectively cutting down the numbers of laboratory animals needed and shortening the drug discovery process. For the first time, Cloe PKä offers pharmaceutical and biotechnology companies the ability to screen hundreds of compounds within minutes and provides a way to foresee problems associated with administering the compound.

Cloe PKä's software effectively provides a virtual model of the human body and delivers an accurate estimation of the likely amounts and distribution over time of compound present in the blood and major organs after it has been given in pill or injection form. This is critical information for evaluating whether a pharmaceutical compound would stay in the patient's body long enough to be an effective drug.

Cloe PKä is a powerful virtual tool that has been designed with a simple user interface so that it can be readily used by a broad range of drug discovery researchers, including chemists and scientists concerned with improving their nascent pharmaceutical compounds.

Cloe PKä is part of a suite of technologies that Cyprotex has created for the pharmaceutical and biotechnology sectors to enable better ranking, selection and optimisation of new compounds in drug discovery. The addition of Cloe PKTM predictive software to its existing automated screening adds another level of service and hence an additional income stream to the Company's business model.

"Cloe" stands for "Cyprotex Lead Optimisation Engine", reflecting how the Company's family of services combine to provide operational efficiencies to its clients engaged in drug discovery.

David Leahy, Chief Scientific Officer at Cyprotex, said: "Drug discovery researchers are faced with the task of having to improve the success rates of their projects, yet they often have to base their decision-making on incomplete and confusing information. We are offering an easy to use interpretative tool in Cloe PKä that quickly identifies potential failures and at the same time indicates the priorities in valuable drug discovery resources."

- Ends -

For further information:

Cyprotex PLC Dr David Leahy, Chief Scientific Officer [d.leahy@cyprotex.com](mailto:d.leahy@cyprotex.com) Tel: 44 (0) 1625 505100 [www.cyprotex.com](http://www.cyprotex.com)

Media enquiries:

Bankside Henry Harrison-Topham / Heather Salmond [heather.salmond@bankside.com](mailto:heather.salmond@bankside.com) Tel: 44 (0) 20 7444 4140 [www.bankside.com](http://www.bankside.com)

Notes to editors:

## Cyprotex PLC

Cyprotex is a specialist provider of technology and information to evaluate and optimise key properties of potential drugs that determine how well they will be absorbed, distributed, metabolised and excreted by the body. This provides pharmaceutical partners with a sound basis for decision-making regarding compound selection and design that takes into account how the compound will behave in the body. Cyprotex predicts the likely outcome of administering either orally or intravenously-administered compounds by modelling human and rat physiology. Predictions require basic compound information that can be derived in the laboratory using established methods, all of which are routinely performed by Cyprotex's experimental capability. This unique combination of technologies is aimed at improving pharmaceutical productivity by improving the quality of compound libraries and drug candidates progressing through the drug pipeline. Cyprotex is UK-based and listed on the London Stock Exchange (CRX).